[ad_1]
Remedivis, an antiviral drug developed by the American company Gilead Sciences, has been discussed among medical scientists to fight the coronavirus. Meanwhile, American scientists have claimed that they have found clear evidence of the effectiveness of this drug in treating the crown. However, a few days ago it became known that the drug had failed in a Chinese trial. As a result, the World Health Organization (WHO) has not yet officially recognized the drug. However, the United States has allowed the use of corrective therapy in the treatment of seriously ill crown patients, regardless of these factors.
Last Friday, the President of the United States, Donald Trump, made the announcement along with Dan O’Day, CEO of Gilead Science. Previously, the United States Food and Drug Administration (FDA) authorized hospitals to use the drug. The United States decided to use the drug at a time when the total number of infected people in the country exceeded 11.32 million and the death toll exceeded 8,000 as of Saturday.
Earlier, at a White House press conference on April 29, the director of the United States National Institute of Allergy and Infectious Diseases, Dr. demanded that there be clear evidence of the effectiveness of remedies to prevent the virus from the crown. Anthony Fauchi. “We have seen that about 31 percent of the remedies are working faster to cure coronary artery disease,” he said, citing his own evidence. Many are recovering in about 11 days. ” Fawcett said the Red Decree was applied to a total of 1,063 patients with coronary artery disease at six locations in the United States, Europe and Asia to understand how effective it is. Remedivir has been found to effectively prevent Kovid-19 infection in the body. There were no side effects in the patients.
However, according to Fausi, it is better to apply this medication to patients who are not admitted to the hospital at the moment. Those who have the ability to cope with the milder or crown symptoms, even if the medication is not applied at this time. Because remediation is not yet available.
After that, the White House approved the use of remediation. According to the FDA, the drug will be administered first to those with severe Covid-19, low blood oxygen levels, and those who are placed on a ventilator. NBC News.
[ad_2]
